Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miltefosine for Mucocutaneous Leishmaniasis
NCT01050907Phase 2Completed
- Sponsor
- Knight Therapeutics Inc.
- Start
- May 2010
- Primary completion
- Feb 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of miltefosine in mucosal leishmaniasis (ML), cutaneous leishmaniasis (CL), sponsored by Knight Therapeutics Inc.. Started May 2010; status: completed.
02
Drugs
miltefosine
03
Conditions
mucosal leishmaniasis (ML)cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT01050907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01050907.